25 Recruiting Studies Using Binimetinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Binimetinib
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
📍 Providence Portland Medical Center — Portland, Oregon
BRAF NP_004324.2:p.V600M
View Study & Checklist ➔A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
📍 Adventist Health System/Sunbelt, Inc. — Orlando, Florida
Melanoma
View Study & Checklist ➔Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Solid Tumor
View Study & Checklist ➔Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
📍 O'Neal Comprehensive Cancer Center — Birmingham, Alabama
Stage III Breast Cancer
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Melanoma (Skin)
View Study & Checklist ➔Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Uveal Melanoma
View Study & Checklist ➔Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Biliary Tract Carcinoma
View Study & Checklist ➔Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Non-small Cell Carcinoma
View Study & Checklist ➔Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist ➔Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Exocrine Pancreas Carcinoma
View Study & Checklist ➔Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
📍 M D Anderson Cancer Center — Houston, Texas
Clinical Stage IV Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Melanoma Stage III
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
📍 UCLA Medical Center — Los Angeles, California
Metastatic Uveal Melanoma
View Study & Checklist ➔Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Hairy Cell Leukemia
View Study & Checklist ➔Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
📍 Moffitt Cancer Center — Tampa, Florida
Melanoma Stage III
View Study & Checklist ➔Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
📍 University of Iowa — Iowa City, Iowa
Metastatic Melanoma
View Study & Checklist ➔The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
📍 St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Solid Tumors
View Study & Checklist ➔Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
📍 Boston Medical Center — Boston, Massachusetts
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
📍 Children's Hospital Colorado — Aurora, Colorado
Adamantinous Craniopharyngioma
View Study & Checklist ➔A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acral Lentiginous Melanoma
View Study & Checklist ➔A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
📍 Highlands Oncology Group, PA — Fayetteville, Arkansas
Melanoma
View Study & Checklist ➔